InSilico Medicine Cayman TopCo (HKSE:03696) Share Price

Company Profile

Business description
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
Contact
Hong Kong Science Park
Unit 310, 3rd Floor, Building 8W, Phase 2
Pak Shek Kok, New Territories
Hong Kong
HKG
http://www.insilico.com
Sector
Technology
Stock type
Sensitive
Industry
Software - Infrastructure
Fiscal Year End
31 December 2026
Employees
317

Recommended

Aussie stock exchange remains materially undervalued despite growing cost concerns.

Roy Van Keulen | 29 May 2026

Questions surround Australia’s largest data center developer and its growing pipeline.

Yingqi Tan, CFA | 29 May 2026

The e-commerce business continues its sales momentum despite challenging backdrop.

Johannes Faul, CFA | 28 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,965.00	77.80	0.88%
CAC 40	8,183.34	5.53	-0.07%
DAX 40	25,104.70	12.45	0.05%
Dow JONES (US)	51,032.46	363.49	0.72%
FTSE 100	10,409.28	16.68	-0.16%
HKSE	25,182.39	176.23	0.70%
NASDAQ	26,972.62	55.15	0.20%
Nikkei 225	66,329.50	1,636.38	2.53%
NZX 50 Index	13,244.55	38.44	0.29%
S&P 500	7,580.06	16.43	0.22%
S&P/ASX 200	8,731.70	73.10	0.84%
SSE Composite Index	4,068.57	30.07	-0.73%